Latest Headlines

  1. Noul Supplies AI Diagnostic Platform miLab™ To Charité, Europe's Leading University Hospital 10/28/2025

    Noul Co., Ltd.(CEO David Lim), an AI-driven blood and cancer diagnostics company, announced the supply of its AI-based malaria diagnostic solution miLab™ MAL to Charité – Universitätsmedizin Berlin, Germany's largest and most prestigious university hospital.

  2. Cepheid Announces World Health Organization Prequalification Of The Xpert® MTB/XDR Test 10/28/2025

    Cepheid today announced that its Xpert® MTB/XDR test has been awarded prequalification status by the World Health Organization (WHO), marking a new milestone in the global fight against tuberculosis (TB).

  3. InstantGMP Launches Fully Integrated Laboratory Information Management System (LIMS) Software 10/28/2025

    InstantGMP™, the innovators in manufacturing and quality management software for the pharmaceutical, supplement, and biotech industries, today announced the release of its new Laboratory Information Management System (LIMS), a fully integrated quality control (QC) module built directly into the InstantGMP manufacturing platform.

  4. QIAGEN Marks 4,000th QIAcube Connect Placement, Reaffirming Leadership In Automated Sample Processing 10/28/2025

    QIAGEN today announced the 4,000th placement of its QIAcube Connect instrument, a significant milestone in driving automation adoption for sample processing across life science and diagnostic labs.

  5. Simple Saliva Test Could Revolutionise Heart Failure Detection 10/27/2025

    Detecting acute heart failure in the future could be as simple as testing a saliva sample.

  6. Expanded Cap Carrier Range Improves Sample Management Flexibility 10/27/2025

    Azenta Life Sciences has introduced new 24- and 48-format cap carriers, alongside its existing 96-format solution, to provide researchers with scalable options to streamline sample tube processing workflows, across a wide range of applications.

  7. Co-Diagnostics Signs Definitive Agreement With Arabian Eagle In The Kingdom Of Saudi Arabia To Establish CoMira Diagnostics And Localize Co-Dx™ PCR Platform Across The Middle East 10/27/2025

    Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has entered into a definitive agreement with Arabian Eagle Manufacturing ("Arabian Eagle"), a regional manufacturing and distribution company based in the Kingdom of Saudi Arabia ("KSA") to form a joint venture ("JV"), CoMira Diagnostics ("CoMira"), to research, develop, manufacture, assemble, distribute, and commercialize Co-Dx technologies and intellectual property, including the Company's upcoming Co-Dx™ PCR point-of-care platform*, within KSA and 18 other countries (the "Territory") throughout the Middle East and North Africa ("MENA").

  8. Fibronostics Acquires Stone Clinical Laboratories To Advance MASH/MASLD Diagnostics 10/27/2025

    Fibronostics, a global leader in non-invasive diagnostics for metabolic and liver diseases, today announced the completion of its acquisition of Stone Clinical Laboratories, LLC, a leading provider of advanced laboratory services in the United States.

  9. Labcorp To Offer First FDA-Cleared Blood Test To Rule out Alzheimer's-Related Amyloid Pathology In Primary Care Settings 10/23/2025

    Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer the Elecsys pTau181 test, the only blood test cleared by the U.S. Food and Drug Administration (FDA) to aid in the initial assessment for Alzheimer's disease and other causes of cognitive decline in the primary-care setting.

  10. Biodesix Announces Expanded Bio-Rad Laboratories Partnership Agreement To Develop Droplet Digital™ PCR High Complexity Assays 10/22/2025

    Biodesix, Inc. (NYSE: BDSX), a leading diagnostics solutions company, today announced the signing of an expanded partnership agreement under which Biodesix will conduct the development, clinical validation, and regulatory submissions of in vitro diagnostic (IVD) assays to enable highly sensitive detection of multiple genomic markers focused on oncology applications, utilizing Bio-Rad’s Droplet Digital™ PCR (ddPCR™) technology on Bio-Rad’s QX600 platform.